NEW YORK – Genetic engineering company Sherlock Biosciences and Dartmouth-Hitchcock Health (D-HH), an academic health system based in New Hampshire, said on Wednesday that they are partnering to launch a clinical study of the Sherlock CRISPR SARS-CoV-2 kit.